Additions:
**""ImmuneRegen"" ""BioSciences"" Announces Promising Data On Homspera Suggesting Potential As A Co-Therapeutic Agent**
""ImmuneRegen"" ""BioSciences"", a wholly owned subsidiary of ""IR"" ""BioSciences"" Holdings, Inc. (OTC Bulletin Board: IRBO), announced today that data obtained by the Company on its Substance P analog, Homspera, suggests that the compound has potential value as a co-therapeutic agent or vaccine adjuvant. Studies performed in animal models of influenza and acute radiation syndrome have revealed the potential capability of Homspera to enhance the action of approved antiviral medications as well as to provide adjunctive impact on antitumor radiation therapy.
""ImmuneRegen"" ""BioSciences"", a wholly owned subsidiary of ""IR"" ""BioSciences"" Holdings, Inc. (OTC Bulletin Board: IRBO), announced today that data obtained by the Company on its Substance P analog, Homspera, suggests that the compound has potential value as a co-therapeutic agent or vaccine adjuvant. Studies performed in animal models of influenza and acute radiation syndrome have revealed the potential capability of Homspera to enhance the action of approved antiviral medications as well as to provide adjunctive impact on antitumor radiation therapy.
Deletions:
""ImmuneRegen"" BioSciences, a wholly owned subsidiary of IR ""BioSciences"" Holdings, Inc. (OTC Bulletin Board: IRBO), announced today that data obtained by the Company on its Substance P analog, Homspera, suggests that the compound has potential value as a co-therapeutic agent or vaccine adjuvant. Studies performed in animal models of influenza and acute radiation syndrome have revealed the potential capability of Homspera to enhance the action of approved antiviral medications as well as to provide adjunctive impact on antitumor radiation therapy.
Additions:
Rubinsky co-authored the paper with Dr. Gary Onik, director of surgical imaging at Florida Hospital Celebration Health. They founded the Oncobionic Company two years ago to commercialize IRE. Oncobionic is in the process of being sold to ""AngioDynamics"", a New York-based manufacturer of medical devices for minimally invasive surgery.
